The Scientist explored the work of a researcher who had an unexpected finding while developing a novel anti-tau therapy.
Axsome Therapeutics said it would submit its Alzheimer’s disease treatment for FDA approval despite mixed results from two ...
Axsome Therapeutics (AXSM) stock fell 12% Monday after the company reported mixed Phase 3 results for its drug AXS-05 in the ...
The Alzheimer’s epidemic continues to cast a shadow over the lives of millions. This disease erodes memories and cognitive ...
Axsome Therapeutics said on Monday its experimental treatment for the Alzheimer's disease-related agitation met the main goal of a late-stage trial.
A common medication may help prevent dementia and Alzheimer's disease—but researchers are still trying to figure out why, and ...
The small miracles that 2024 brought to our lives lay the groundwork for new revolutionary treatments that are being prepared ...
As the year comes to a close, experts from the Alzheimer's Association reflect on some of the hopeful advances in diagnosis, ...
The first pill to slow down the progression of Alzheimer’s disease is being studied for use on the NHS ...
Even as new drugs come to market, further study appears to point to infections as a possible cause for the debilitating ...
Alzheimer’s Association President and CEO Dr. Joanne Pike said “This is real progress,” when it came to approving the drug being used on patients riddled with the disease. The Washington ...
“There have been several new drugs recently approved by the Food and Drug Administration for treating Alzheimer’s disease. What these do is to attack the amyloid deposits that occur in the ...